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Background. The 6-minute walk test (6-MWT) is used to assess patients with chronic heart failure (CHF). The prognostic
significance of the 6-MWTdistance during long-term followup (>5 years) is unclear.Methods. 1,667 patients (median [inter-quartile
range, IQR]) (age 72 [65–77]; 75%males) with heart failure due to left ventricular systolic impairment undertook a 6-MWT as part
of their baseline assessment and were followed up for 5 years. Results. At 5 years’ followup, those patients who died (n = 959) were
older at baseline and had a higher log NT pro-BNP than those who survived to 5 years (n = 708). 6-MWT distance was lower in
those who died [163 (153)m versus 269 (160)m; P < 0.0001]. Median 6-MWT distance was 300 (150–376)m, and quartile ranges
were<46m, 46–240m, 241–360m, and>360m. 6-MWTdistancewas a predictor of all-causemortality (HR0.97; 95%CI 0.96-0.97;
Chi-square = 184.1; P < 0.0001). Independent predictors of all-cause mortality were decreasing 6-MWT distance, increasing age,
increasingNYHA classification, increasing logNTpro-BNP, decreasing diastolic blood pressure, decreasing sodium, and increasing
urea.Conclusion.The6-MWT is an important independent predictor of all-causemortality following long-term followup in patients
with CHF.
1. Introduction
Functional capacity is strongly related to survival in patients
with chronic heart failure (CHF) [1]. Although cardiopul-
monary exercise testing (CPET) withmetabolic gas exchange
measurements is perhaps the “gold standard” method for
assessing exercise capacity, it is not widely available, and so
more simple tests are commonly used [2].The 6-minute walk
test (6-MWT) is reproducible and sensitive to changes in
quality of life [3–5]. It is a self-paced, submaximal test, and
exercise intensity mimics activities of daily living in patients
withmild-to-moderate heart failure [6–9].Thus, the 6-MWT
may suit patients with CHF who may experience symptoms
such as breathlessness below their peak exercise capacity.
We have previously reported that decreasing 6-MWTdis-
tance was an independent predictor of increasing mortality
in patients with left ventricular systolic dysfunction but that
it was a less potent single predictor than N-terminal pro-
brain natriuretic peptide (NT pro-BNP) [10]. Others have
shown that the 6-MWT distance is a less powerful predictor
of outcome than some variables, such as VE/VCO
2
slope and
peak oxygen uptake derived from CPET [11].
The aim of the present study was to assess the long-term
(>5 years) prognostic significance of the 6-MWT distance in
a large sample of patients with CHF.
2. Methods
The Hull and East Riding Ethics Committee approved the
study, and all patients provided informed consent for partic-
ipation. Clinical information obtained included past medical
history and drug and smoking history. Clinical examination
included assessment of body mass index (BMI), heart rate,
rhythm, and blood pressure (BP). Heart failure was defined as
current symptoms of heart failure, or a history of symptoms
controlled by ongoing therapy, in the presence of reduced
left ventricular (LV) systolic function on echocardiography
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and in the absence of any other cause for symptoms [12, 13].
2D echocardiography was carried out by one of three trained
operators. LV function was assessed by estimation on a scale
of normal, mild, mild-to-moderate, moderate, moderate-to-
severe, and severe impairment. LV ejection fraction (LVEF)
was calculated using Simpson’s formula, where possible, from
measurements of end-diastolic and end-systolic volumes on
apical 2D views, following the guidelines of Schiller et al. [14]
and LVSD was diagnosed if LVEF was <45%.
The 6-MWT was conducted following a standardised
protocol [9, 10]. A 15mflat, obstacle-free corridor, with chairs
placed at either end, was used. Patients were instructed to
walk as far as possible, turning 180∘ every 15m in the allotted
time of 6min. Patients were able to rest, if needed, and the
time remaining was called every second minute [15]. Patients
were excluded if they were unable to walk without assistance
from another person (not including mobility aids), or if they
were unable to exercise because of noncardiac limitations.
Patients walked unaccompanied so as not to influence walk-
ing speed. After 6min, patients were instructed to stop and
the total distance covered was measured to the nearest metre.
Standardised verbal encouragement was given to patients
after 2min and 4min. If a patient could not undertake the
6-MWT, a distance of 0m was recorded.
2.1. Statistical Analysis. Continuous variables are presented
as median with interquartile range (IQR) or standard
deviation (SD) and categorical data as percentages. Con-
tinuous variables were assessed for normality by the
Kolmogorov-Smirnov test. NT pro-BNP was normalised
by log-transformation for analysis. Differences between
those who survived to five years and those who did not
were determined by the independent samples t-test or
Pearson’s Chi-square test. No survivor was followed up for
less than 5 years. We used receiver operating characteristic
(ROC) curves to assess the predictive power of variables and
report the area under the curve (AUC) with 95% confidence
intervals (CI), sensitivity, specificity, and optimal cut-points.
To define the optimal cut-point, we used the point closest to
the upper left corner of the ROC curve, often known as the
(0, 1) criterion.
We used Kaplan-Meier curves to display mortality data
using the guidance of Pocock et al. [16]. For illustration, 6-
MWT distance data were divided into quartiles (≤45m, 46–
240m, 241–360m, and>360m). Cox regressionmodels (uni-
variable and multivariable) were used to develop predictor
models using all baseline variables. We used multivariable
Cox proportional hazards model using the backward like-
lihood ratio method (P value for entry was <0.05; P value
for removal was >0.1) to identify independent predictors of
all-cause mortality from candidate predictor variables. The
assumption of proportionality was tested for each variable
using the method of Grambsch andTherneau [17].
To minimise the risk of “overfitting,” we were guided
by Peduzzi and colleagues [18, 19] who suggested an events
per variable ratio of 10 : 1. To determine the robustness of
our model(s), we performed bootstrapping based on 1,000
stratified samples. We checked for colinearity by calculating
Pearson correlation coefficients. We used a cut-off value of
0.3 to identify colinearity. SPSS version 19.0 (IBM, New York,
USA) was used to analyse the data. An arbitrary level of 5%
statistical significance was used throughout (two-tailed). We
followed the guidance of Perneger [20] and did not adjust for
multiple testing in order to avoid the inflation of type I error.
The primary outcome measure was all-cause mortality.
3. Results
1,667 patients (median (interquartile range, IQR)) (age 72
(65–77); 75% males) with heart failure due to left ventricular
systolic impairment were included in the study. At 5-year
followup, those patients who died (𝑛 = 959) were, at
baseline, older and had a lower BMI, higher NYHA class,
lower LVEF, higher creatinine, higher log NT pro-BNP, lower
haemoglobin, and higher urea levels than those who survived
to 5 years (𝑛 = 708; Table 1). 6-MWT distance was lower
in those who died (163 (153)m versus 269 (160)m; 𝑃 <
0.0001). Median 6-MWT distance was 300 (150–376)m, and
quartile ranges for 6-MWT distance were <46m, 46–240m,
241–360m, and>360m. Table 2 shows clinical characteristics
divided by quartiles of 6-MWT distance. There were signif-
icant between-group differences for age, BMI, LVEF, resting
HR, resting systolic/diastolic BP,QRSduration, haemoglobin,
log NT pro-BNP, urea, and creatinine (all 𝑃 < 0.05).
Thirteen variables were significantly associated with all-
cause mortality in univariable Cox analysis (Table 3). After
bootstrapping, only 6 variables (6-MWT, age, NT pro-
BNP, NYHA class, diastolic BP, and haemoglobin) remained
statistically significant (Table 4). All variables in Table 1 were
included in a final multivariable Cox model, and six were
independent predictors of all-cause mortality, decreasing 6-
MWT distance, increasing age, increasing NYHA classifica-
tion, increasingNTpro-BNP, decreasing diastolic blood pres-
sure, decreasing sodium, and increasing urea (Table 5). ROC
curve analysis of 6-MWT distance and all-cause mortality at
5 years is shown in Figure 1 (AUC = 0.67; 𝑃 < 0.0001; 95%
CI = 0.64–0.70; the optimal cut-point for 6-MWT distance
was 350m with sensitivity 0.81 and specificity 0.57). Figure 2
shows a Kaplan-Meier survival curve for the patients divided
by quartiles of 6-MWT distance (<46m: event free survival
24%; 46–240m: event free survival 29%; 241–360m: event
free survival 45%; >360m: event free survival 70%).
4. Discussion
We have shown that the 6-MWT is an independent predictor
of all-cause mortality during long-term (5 year) followup in
patients with CHF. To our knowledge, this is the largest study
that has focused on the prognostic value of 6-MWT distance
during extended followup. We have previously shown that 6-
MWT distance is an independent predictor of risk following
medium-term followup (median 36.6 (28–45) months). In
1,592 patients, 212 died representing a crude death rate of
13.3%. Five independent predictors of all-cause mortality
were identified including decreasing 6-MWT distance [10].
Other large-scale studies including the SENIORS trial [21]
(𝑛 = 2, 128 patients, ≥70 years with LVEF ≤ 35% or recent
hospital admission) have also shown that 6-MWT distance
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Table 1: Baseline characteristics of patients [mean (SD)] divided by survival to >5 years.
Variables Dead (𝑛 = 959) Alive (𝑛 = 708) 𝑃 value
Age (years) 74.1 (8.9) 67.9 (10.6) <0.0001
Males (%) 73 75 0.184




LVEF (%) 33 (10) 36 (9) <0.0001
FEV1/FVC (%) 66 (16) 70 (16) <0.0001
Resting HR (beats⋅min−1) 76 (18) 74 (20) 0.165
Resting systolic BP (mmHg) 132 (26) 133 (24) 0.158
Resting diastolic BP (mmHg) 74 (14) 78 (14) <0.0001
QRS duration (ms) 121 (32) 112 (29) <0.0001
Haemoglobin (g⋅dL−1) 13.0 (1.7) 13.9 (1.5) <0.0001
Log NT pro-BNP∗ 7.7 (1.2) 6.7 (1.3) <0.0001
Sodium (mmol⋅L−1) 139 (4) 139 (3) 0.652
Potassium (mmol⋅L−1) 4.4 (0.5) 4.4 (0.5) 0.777
Urea (mmol⋅L−1) 9.3 (4.7) 7.1 (3.6) <0.0001
Creatinine (u⋅moL−1) 130 (51) 110 (55) <0.0001
Diuretic (%) 83 84 0.760
ACE-inhibitor (%) 78 77 0.348
Beta-blocker (%) 73 69 0.322
Spironolactone (%) 22 20 0.202
6-MWT (m) 163 (153) 269 (160) <0.0001
NYHA: New York Heart Association; BMI: body mass index; LVI: left ventricular impairment; LVEF∗: left ventricular ejection fraction available in 67% of
patients; 6-MWT: 6-min walk test; BP: blood pressure; log NT pro-BNP (pg⋅mL−1)∗ available in 92% of patients.
Table 2: Clinical characteristics separated by quartiles of 6-MWT distance in patients with CHF (mean ± SD).
Variables ≤45m 46–240m 241–360m >360m 𝑃 value
Age (years) 72.4 (10.6) 72.9 (9.6) 71.3 (8.8) 64.9 (10.6) <0.0001
BMI (kg⋅m−2) 27.5 (4.5) 27.7 (5.2) 28.5 (5.8) 28.9 (6.8) 0.002
LVEF (%) 32.0 (10.0) 35.1 (10.7) 34.6 (9.2) 36.2 (9.3) <0.0001
FEV1/FVC (%) 66.4 (17.7) 67.5 (15.0) 67.3 (16.5) 68.8 (16.4) 0.257
Resting HR (beats⋅min−1) 80 (36) 75 (17) 73 (17) 72 (17) <0.0001
Resting systolic BP (mmHg) 129 (29) 134 (25) 136 (23) 135 (23) <0.0001
Resting diastolic BP (mmHg) 74 (14) 77 (15) 77 (14) 80 (14) <0.0001
QRS duration (ms) 117 (31) 119 (33) 120 (32) 114 (30) 0.045
Haemoglobin (g⋅dL−1) 13.0 (1.9) 13.2 (1.7) 13.6 (1.5) 14.1 (1.4) <0.0001
Log NT pro-BNP 7.5 (1.4) 7.3 (1.4) 7.0 (1.2) 6.5 (1.3) <0.0001
Sodium (mmol⋅L−1) 138 (3.9) 139 (3.8) 139 (3.3) 139 (3.0) 0.241
Potassium (mmol⋅L−1) 4.4 (0.6) 4.4 (0.5) 4.4 (0.5) 4.4 (0.5) 0.382
Urea (mmol⋅L−1) 9.2 (5.0) 8.5 (4.7) 7.9 (3.9) 6.7 (3.8) <0.0001
Creatinine (u⋅moL−1) 125 (52) 121 (49) 116 (44) 107 (65) <0.0001
is an independent predictor of mortality over a modest time
period (mean followup: 21 months) [21]. Another study [22]
(mean followup 34 months) has also confirmed the prognos-
tic value of 6-MWT distance for predicting cardiac-related
death in patients with mild-to-moderate CHF. Long-term
studies have been reported in patients with stable coronary
heart disease, including the Heart and Soul Study [23] which
followed up patients for a median of 8.0 (4.2–9.0) years
and showed that 6-MWT distance predicted cardiovascular
events and provided similar prognostic value to treadmill
exercise capacity. A limitation of the study was a small sample
size (𝑛 = 556) and a limited number of events (184 deaths).
A number of studies have shown that 6-MWT distance
is a less powerful predictor of outcome in patients with CHF
than variables derived from CPET such as VE/VCO
2
slope
and peak oxygen uptake [24]. Opasich and colleagues [25]
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Table 3: Unadjusted univariable predictors of all-cause mortality in patients with CHF (in order of Chi-square value).
Variables 𝑃 value HR 95% CI Chi-square
Lower Upper
Log NT pro-BNP <0.0001 1.63 1.53 1.74 230.8
6-MWT (m)∗ <0.0001 0.968 0.964 0.973 184.1
Age (years) <0.0001 1.05 1.04 1.06 137.2
Urea (mmol⋅L−1) <0.0001 1.05 1.05 1.06 128.9
Haemoglobin (g⋅dL−1) <0.001 0.84 0.81 0.87 96.9
NYHA class <0.0001 1.64 1.48 1.82 89.0
Creatinine (u⋅moL−1)∗ <0.001 1.023 1.016 1.029 58.3
Diastolic BP (mmHg) <0.001 0.99 0.98 0.99 42.4
Sodium (mmol⋅L−1) <0.001 0.96 0.94 0.97 27.1
QRS duration (ms)∗ <0.001 1.05 1.03 1.07 18.3
BMI (kg⋅m−2) <0.001 0.98 0.97 0.99 14.6
Systolic BP (mmHg) <0.001 1.00 0.99 1.00 8.9
Heart rate (beats⋅min−1) 0.01 1.00 1.00 1.01 7.1
HR: hazard ratio; 95% CI: 95% confidence intervals; 6-MWT: 6-minute walk test; NYHA: New York Heart Association; LVI: left ventricular impairment; ∗HR
reported for 10-unit increment.
Table 4: Bootstrap model based on 1000 stratified samples. Univariable predictors listed in order of magnitude of 𝑃 value.
Variables 𝐵
Bootstrap
Bias SE P value 95% CI
Lower Upper
Log NT pro-BNP 0.489 −0.001 0.35 0.001 0.418 0.556
6-MWT (m) −0.002 0.0001 0.0001 0.001 −0.002 −0.001
Age (years) 0.042 −0.001 0.004 0.001 0.033 0.050
NYHA class 0.136 0.004 0.060 0.023 0.027 0.263
Diastolic BP (mmHg) −0.007 0.0001 0.003 0.030 −0.013 −0.001
Haemoglobin (g⋅dL−1) −0.041 −0.002 0.021 0.049 −0.082 0.002
Urea (mmol⋅L−1) 0.024 −0.002 0.014 0.068 −0.006 0.047
Sodium (mmol⋅L−1) −0.014 −0.001 0.010 0.182 −0.034 0.007
QRS duration (m⋅s−1) 0.001 0.0001 0.001 0.253 −0.001 0.004
Systolic BP (mmHg) 0.001 0.0001 0.002 0.528 −0.002 0.005
Creatinine (u⋅moL−1) 0.001 0.0001 0.001 0.667 −0.001 0.004
Heart rate (beats⋅min−1) 0.000 0.0001 0.002 0.736 −0.002 0.005
Potassium (mmol⋅L−1) −0.001 0.0001 0.073 0.982 −0.143 0.137
SE: standard error; 95% CI: 95% confidence intervals; 6-MWT: 6-minute walk test; NYHA: New York Heart Association; LVI: left ventricular impairment.
Table 5: Multivariable predictors of long-term all-cause mortality in patients with CHF: final model (listed in order of magnitude of Wald
statistic).
Variables 𝑃 value Wald HR 95% CI
Lower Upper
Log NT pro-BNP <0.0001 86.3 1.393 1.299 1.494
6-MWT (m)∗ <0.0001 57.2 0.980 0.974 0.985
Age (years) <0.0001 29.9 1.026 1.017 1.036
Diastolic BP (mmHg) 0.001 12.8 0.990 0.984 0.995
Urea (mmol⋅L−1) 0.002 9.5 0.980 0.974 0.985
Sodium (mmol⋅L−1) 0.052 3.8 0.978 0.957 1.000
HR: hazard ratio; 95% CI: 95% confidence intervals; 6-MWT: 6-minute walk test; NYHA: New York Heart Association; ∗HR reported for 10-unit increment.














Figure 1: Receiver operating characteristic curve showing value of
the 6-MWT for predicting all-cause mortality at 5 years in patients
with CHF (AUC = 0.67; 𝑃 < 0.0001; 95% CI = 0.64–0.70; sensitivity





















𝜒2 = 16.0; P ≤ 0.0001
𝜒2 = 72.7; P ≤ 0.0001
𝜒2 = 235.6; P ≤ 0.0001
Figure 2: Kaplan-Meier survival curve showing quartiles of 6-
MWT distance (m) (<46m, event free survival 24%; 46–240m,
event free survival 29%; 241–360m, event free survival 45%;>360m,
event free survival 70%).
concluded that 6-MWT distance (mean followup 387 ± 177
days) does not provide complimentary prognostic informa-
tion or should be substituted for peak oxygen consumption.
In a study of only 253 patients with either systolic or diastolic
heart failure in whom there were 43 cardiac events over
4 years, Guazzi et al. [11] found that although 6-MWT
distance correlated with peak oxygen uptake and VE/VCO
2
slope, there was no significant association between 6-MWT
distance and survival. However, CPET-derived variables were
predictors of prognosis.
Most studies using CPET variables as potential predictors
of outcome have followed up patients for two years or less.
Studies have reported very short-term (e.g., 6 months or less)
followup [26, 27], 12 months [28–31] or up to 2 years [26, 32–
37]. Few studies have reported tracking periods beyond 3
years [38, 39]. Prognostic models for patients with heart
failure usually contain variables from domains measuring
some aspect of exercise capacity, some indicator of cardiac
function (such as left ventricular ejection fraction), and some
indicator of systemic involvement (such as creatinine). CPET
is not widely available. We show here that the simple and
cheap 6-MWT distance is an easily obtainable variable which
strongly relates to long-term survival in patients with CHF.
4.1. Study Limitations. The 6-MWT is not a test of maximal
exercise capacity but is a test of submaximal exercise perfor-
mance [6].The AmericanThoracic Society [7] advocates that
verbal encouragement should be limited and tone of voice be
controlled during the 6-MWT in an elderly, chronic disease
population.We have followed this approachwith our patients
but different centres will operate different systems.Therefore,
findings from our current study should not be extrapolated to
other populations or to other research centres that may use a
more aggressive 6-MWT coaching style.
4.2. Conclusion. The 6-MWT is an independent predictor
of all-cause mortality following long-term (5-year) followup
in patients with CHF. It provides similar or better discrim-
inatory power than other routinely collected physical and
biochemical variables and, as such, might make a reasonable
target for treatment.
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